Cornelis Francois H, Durack Jeremy C, Morris Michael J, Scher Howard I, Solomon Stephen B
From the Departments of *Radiology and †Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.
Clin Nucl Med. 2017 Dec;42(12):e516-e518. doi: 10.1097/RLU.0000000000001846.
PET/CT-guided interventions using specific radiotracers are promising for detecting avid lesions not well visualized with other imaging methods. A 72-year-old man who initially presented with prostate cancer Gleason 5 + 4 (prostate-specific antigen [PSA] = 7.9 ng/mL) underwent radical prostatectomy and node dissection. Three years after radiation, a rising PSA was observed over 6 months with PSA level reaching 1.08 ng/mL. He was evaluated with prostate-specific membrane antigen-based (PSMA) F-DCFPyL PET/CT, conventional CT, F-FDG PET/CT, and C-choline PET/CT. The PSMA F-DCFPyL PET/CT successfully targeted oligometastatic prostate cancer, whereas the other imaging studies were not correct in assessing disease extent.
使用特定放射性示踪剂的PET/CT引导介入技术有望检测出其他成像方法难以清晰显示的高摄取病变。一名72岁男性，最初诊断为前列腺癌Gleason 5 + 4（前列腺特异性抗原[PSA]=7.9 ng/mL），接受了根治性前列腺切除术和淋巴结清扫术。放疗三年后，PSA在6个月内持续升高，达到1.08 ng/mL。对其进行了基于前列腺特异性膜抗原（PSMA）的F-DCFPyL PET/CT、传统CT、F-FDG PET/CT和C-胆碱PET/CT检查。PSMA F-DCFPyL PET/CT成功定位了寡转移前列腺癌，而其他影像学检查在评估疾病范围方面并不准确。
